Pharmacogenetics as Innovative Approach for Phase I Clinical Studies in Cancer Patients
نویسندگان
چکیده
منابع مشابه
Innovative Clinical Perspectives for CIK Cells in Cancer Patients
Cytokine-induced killer (CIK) cells are T lymphocytes that have acquired, in vitro, following extensive manipulation by Interferon gamma (IFN-γ), OKT3 and Interleukin 2 (IL-2) addition, the expression of several Natural Killer (NK) cell-surface markers. CIK cells have a dual "nature", due to the presence of functional TCR as well as NK molecules, even if the antitumoral activity can be traced b...
متن کاملi Engaging as an innovative approach to engage patients in their own fall prevention care
Decreasing patient fall injuries during hospitalization continues to be a challenge at the bedside. Empowering patients to become active participants in their own fall prevention care could be a solution. In a previous study, elderly patients recently discharged from a United States hospital expressed a need for nurses to give and repeat directives about fall prevention; when the nurse left a b...
متن کاملEOS starts Phase I in cancer patients
September 27, 2010, Milan, Italy. EOS S.p.A. (Ethical Oncology Science) announced today the initiation of the first-in-man trial of E-3810, its oral Dual Selective VEGF/FGF protein kinase inhibitor. Patients with advanced solid tumours not amenable to standard therapy will be recruited to this Phase I open-label, dose-escalation trial evaluating the safety profile of E-3810 in order to determin...
متن کاملI-25: Gamete Cryopreservation for Cancer Patients,Ethical Considerations
Cancer patients often receive gonadotoxic treatments, such as radiation or certain chemotherapies. The doses and regimens used for treatment vary in different individuals and cancers. Recent progress has improved the survival rates of patients with cancer, often using highly aggressive therapies and combinations. This results in growing numbers of cancer survivors, some of whom will be sterile ...
متن کاملI-33: Pharmacogenetics of Reproductive Medicine
Adverse drug reactions (ADRs) are a major problem in drug therapy and drug development. Inter-individual genetic differences can have significant roles in determining an individual’s susceptibility to ADRs. The rapid development of techniques in the area of genome analysis has put the scientific community in a power position and facilitated identification of new pharmacogenomic biomarkers that ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Drug Metabolism & Toxicology
سال: 2012
ISSN: 2157-7609
DOI: 10.4172/2157-7609.1000e110